483
Charles Redfern, MDCharles Redfern, MD – FDA 483, Mar 11, 2022
Record Details
An FDA inspection of Charles Redfern, MD in San Diego, CA, a clinical investigator, revealed a significant observation related to the conduct of a clinical study. The firm failed to follow the investigational plan, specifically regarding the administration and completion of PRO-CTCAE questionnaires and adherence to dose modification protocols for study subjects. This indicates a lack of adherence to study protocols during clinical trials.
View Company Profile
ID · 0a943d29-e1e3-40a1-bcdb-5d94276a0394
Document or profile
One record shows the event. A profile shows the pattern.
Buy this document for the source file and details behind this single event.
Choose full profile access to connect related records, sites, people, citations, and enforcement history in one view.